New drug cocktail aims to shrink Hard-to-Treat lymphomas
NCT ID NCT06563596
First seen Feb 24, 2026 · Last updated Jun 11, 2026 · Updated 10 times
Summary
This study tests whether a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) can safely shrink tumors in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. About 45 adults who have already tried at least one other therapy will receive the drug combo. The main goal is to see how many patients achieve a complete metabolic response, meaning no signs of active cancer on scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Email: •••••@•••••
Contact
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.